Dr. Martens (DOCS) Competitors

GBX 62.42 +1.73 (+2.84%)

As of 04:59 AM Eastern

DOCS vs. RMG, SPT, VTY, GEN, and WIX

Should you buy Dr. Martens stock or one of its competitors? MarketBeat compares Dr. Martens with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Martens include Royal Mail (RMG), Spirent Communications (SPT), Vistry Group (VTY), Genuit Group (GEN), and Wickes Group (WIX). These companies are all part of the "computer software" industry.

How does Dr. Martens compare to Royal Mail?

Dr. Martens (LON:DOCS) and Royal Mail (LON:RMG) are both small-cap computer software companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

32.2% of Dr. Martens shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Dr. Martens had 1 more articles in the media than Royal Mail. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Royal Mail. Dr. Martens' average media sentiment score of 0.00 equaled Royal Mail'saverage media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Royal Mail	Neutral

Dr. Martens presently has a consensus price target of GBX 3,057, suggesting a potential upside of 4,797.08%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Royal Mail.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Royal Mail	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Martens has a net margin of 1.95% compared to Royal Mail's net margin of 0.00%. Dr. Martens' return on equity of 4.40% beat Royal Mail's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	1.95%	4.40%	8.12%
Royal Mail	N/A	N/A	N/A

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 4.1%. Royal Mail pays an annual dividend of GBX 0.17 per share. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royal Mail pays out 27.4% of its earnings in the form of a dividend.

Dr. Martens has higher earnings, but lower revenue than Royal Mail. Royal Mail is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£785M	0.77	£68.97M	£1.70	36.72
Royal Mail	£12.71B	0.00	N/A	£0.61	N/A

Summary

Dr. Martens beats Royal Mail on 11 of the 14 factors compared between the two stocks.

How does Dr. Martens compare to Spirent Communications?

Spirent Communications (LON:SPT) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Dr. Martens has higher revenue and earnings than Spirent Communications. Dr. Martens is trading at a lower price-to-earnings ratio than Spirent Communications, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spirent Communications	£471M	2.49	£16.67M	£0.01	16,032.26
Dr. Martens	£785M	0.77	£68.97M	£1.70	36.72

Spirent Communications presently has a consensus price target of GBX 199, suggesting a potential upside of 0.10%. Dr. Martens has a consensus price target of GBX 3,057, suggesting a potential upside of 4,797.08%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Spirent Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spirent Communications	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dr. Martens has a net margin of 1.95% compared to Spirent Communications' net margin of 1.53%. Dr. Martens' return on equity of 4.40% beat Spirent Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spirent Communications	1.53%	1.82%	2.77%
Dr. Martens	1.95%	4.40%	8.12%

Spirent Communications has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.241, indicating that its share price is 76% less volatile than the broader market.

57.4% of Spirent Communications shares are held by institutional investors. Comparatively, 32.2% of Dr. Martens shares are held by institutional investors. 22.0% of Spirent Communications shares are held by insiders. Comparatively, 2.8% of Dr. Martens shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dr. Martens had 1 more articles in the media than Spirent Communications. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Spirent Communications. Spirent Communications' average media sentiment score of 0.00 equaled Dr. Martens'average media sentiment score.

Company	Overall Sentiment
Spirent Communications	Neutral
Dr. Martens	Neutral

Summary

Dr. Martens beats Spirent Communications on 10 of the 15 factors compared between the two stocks.

How does Dr. Martens compare to Vistry Group?

Dr. Martens (LON:DOCS) and Vistry Group (LON:VTY) are both small-cap consumer cyclical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£785M	0.77	£68.97M	£1.70	36.72
Vistry Group	£3.61B	0.25	£245.05M	£42.00	6.87

Dr. Martens currently has a consensus price target of GBX 3,057, suggesting a potential upside of 4,797.08%. Vistry Group has a consensus price target of GBX 541.80, suggesting a potential upside of 87.68%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Martens is more favorable than Vistry Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vistry Group	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

Vistry Group has a net margin of 3.82% compared to Dr. Martens' net margin of 1.95%. Dr. Martens' return on equity of 4.40% beat Vistry Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	1.95%	4.40%	8.12%
Vistry Group	3.82%	4.20%	3.43%

Dr. Martens has a beta of 0.241, indicating that its share price is 76% less volatile than the broader market. Comparatively, Vistry Group has a beta of 1.883, indicating that its share price is 88% more volatile than the broader market.

32.2% of Dr. Martens shares are owned by institutional investors. Comparatively, 68.4% of Vistry Group shares are owned by institutional investors. 2.8% of Dr. Martens shares are owned by insiders. Comparatively, 10.0% of Vistry Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vistry Group had 6 more articles in the media than Dr. Martens. MarketBeat recorded 7 mentions for Vistry Group and 1 mentions for Dr. Martens. Vistry Group's average media sentiment score of 0.26 beat Dr. Martens' score of 0.00 indicating that Vistry Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Martens	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vistry Group	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Vistry Group beats Dr. Martens on 10 of the 16 factors compared between the two stocks.

How does Dr. Martens compare to Genuit Group?

Dr. Martens (LON:DOCS) and Genuit Group (LON:GEN) are both small-cap computer software companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, Dr. Martens had 1 more articles in the media than Genuit Group. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Genuit Group. Dr. Martens' average media sentiment score of 0.00 equaled Genuit Group'saverage media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Genuit Group	Neutral

Dr. Martens has higher revenue and earnings than Genuit Group. Genuit Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£785M	0.77	£68.97M	£1.70	36.72
Genuit Group	£602.10M	1.04	£23.57M	£17.80	14.02

Dr. Martens has a beta of 0.241, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Genuit Group has a beta of 1.492, suggesting that its share price is 49% more volatile than the broader market.

Genuit Group has a net margin of 7.51% compared to Dr. Martens' net margin of 1.95%. Genuit Group's return on equity of 6.89% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	1.95%	4.40%	8.12%
Genuit Group	7.51%	6.89%	4.59%

Dr. Martens currently has a consensus price target of GBX 3,057, suggesting a potential upside of 4,797.08%. Genuit Group has a consensus price target of GBX 463.25, suggesting a potential upside of 85.60%. Given Dr. Martens' higher possible upside, analysts clearly believe Dr. Martens is more favorable than Genuit Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Genuit Group	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 4.1%. Genuit Group pays an annual dividend of GBX 12.60 per share and has a dividend yield of 5.0%. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Genuit Group pays out 70.8% of its earnings in the form of a dividend. Genuit Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

32.2% of Dr. Martens shares are held by institutional investors. Comparatively, 74.4% of Genuit Group shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 4.2% of Genuit Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Genuit Group beats Dr. Martens on 11 of the 17 factors compared between the two stocks.

How does Dr. Martens compare to Wickes Group?

Dr. Martens (LON:DOCS) and Wickes Group (LON:WIX) are both small-cap consumer cyclical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

In the previous week, Wickes Group had 1 more articles in the media than Dr. Martens. MarketBeat recorded 2 mentions for Wickes Group and 1 mentions for Dr. Martens. Wickes Group's average media sentiment score of 0.34 beat Dr. Martens' score of 0.00 indicating that Wickes Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Martens	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Wickes Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Martens has higher earnings, but lower revenue than Wickes Group. Wickes Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£785M	0.77	£68.97M	£1.70	36.72
Wickes Group	£1.64B	0.24	£29.25M	£16.40	10.69

Dr. Martens has a beta of 0.241, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Wickes Group has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Wickes Group has a net margin of 2.35% compared to Dr. Martens' net margin of 1.95%. Wickes Group's return on equity of 29.52% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	1.95%	4.40%	8.12%
Wickes Group	2.35%	29.52%	3.77%

Dr. Martens currently has a consensus target price of GBX 3,057, suggesting a potential upside of 4,797.08%. Wickes Group has a consensus target price of GBX 249.17, suggesting a potential upside of 42.14%. Given Dr. Martens' higher probable upside, equities research analysts clearly believe Dr. Martens is more favorable than Wickes Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Wickes Group	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 4.1%. Wickes Group pays an annual dividend of GBX 10.90 per share and has a dividend yield of 6.2%. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Wickes Group pays out 66.5% of its earnings in the form of a dividend. Wickes Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

32.2% of Dr. Martens shares are held by institutional investors. Comparatively, 57.4% of Wickes Group shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 0.4% of Wickes Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Wickes Group beats Dr. Martens on 11 of the 17 factors compared between the two stocks.

Get Dr. Martens News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOCS vs. The Competition

Export

Metric	Dr. Martens	Footwear & Accessories Industry	Cyclical Sector	LON Exchange
Market Cap	£603.77M	£7.63B	£4.01B	£2.78B
Dividend Yield	4.10%	2.12%	3.59%	6.09%
P/E Ratio	36.72	16.47	77.24	365.92
Price / Sales	0.77	36.48	328.69	88,371.87
Price / Cash	14.29	20.28	30.86	27.89
Price / Book	1.65	3.49	3.17	7.70
Net Income	£68.97M	£168.67M	£249.43M	£5.89B
7 Day Performance	-3.21%	6.66%	-0.38%	0.48%
1 Month Performance	-4.72%	7.72%	0.07%	2.53%
1 Year Performance	5.00%	11.57%	1.61%	87.11%

Dr. Martens Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOCS Dr. Martens	3.5224 of 5 stars	GBX 62.43 +2.8%	GBX 3,057 +4,797.1%	+1.6%	£603.77M	£785M	36.72	890	Gap Up
RMG Royal Mail	N/A	N/A	N/A	N/A	£1.98B	£12.71B	339.34	100
SPT Spirent Communications	0.2831 of 5 stars	GBX 198.80 flat	GBX 199 +0.1%	+4.0%	£1.17B	£471M	16,032.26	1,526
VTY Vistry Group	4.4469 of 5 stars	GBX 339.86 +3.7%	GBX 556.60 +63.8%	-54.9%	£1.08B	£3.61B	8.09	4,400	News Coverage Analyst Forecast
GEN Genuit Group	4.5801 of 5 stars	GBX 258.65 +5.6%	GBX 463.25 +79.1%	-38.9%	£649.79M	£602.10M	14.53	2,700	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DOCS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Summary

How does Dr. Martens compare to Spirent Communications?

Summary

How does Dr. Martens compare to Vistry Group?

Summary

How does Dr. Martens compare to Genuit Group?

Summary

How does Dr. Martens compare to Wickes Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Do insiders and institutionals hold more shares of DOCS or RMG?

Does the media prefer DOCS or RMG?

Do analysts rate DOCS or RMG?

Is DOCS or RMG more profitable?

Is DOCS or RMG a better dividend stock?

Which has better earnings & valuation, DOCS or RMG?

Summary

How does Dr. Martens compare to Spirent Communications?

Which has higher earnings and valuation, SPT or DOCS?

Do analysts recommend SPT or DOCS?

Is SPT or DOCS more profitable?

Which has more risk and volatility, SPT or DOCS?

Do institutionals and insiders have more ownership in SPT or DOCS?

Does the media prefer SPT or DOCS?

Summary

How does Dr. Martens compare to Vistry Group?

Which has better valuation and earnings, DOCS or VTY?

Do analysts rate DOCS or VTY?

Is DOCS or VTY more profitable?

Which has more risk and volatility, DOCS or VTY?

Do insiders & institutionals hold more shares of DOCS or VTY?

Does the media favor DOCS or VTY?

Summary

How does Dr. Martens compare to Genuit Group?

Does the media favor DOCS or GEN?

Which has preferable valuation and earnings, DOCS or GEN?

Which has more volatility & risk, DOCS or GEN?

Is DOCS or GEN more profitable?

Do analysts rate DOCS or GEN?

Is DOCS or GEN a better dividend stock?

Do insiders and institutionals hold more shares of DOCS or GEN?

Summary

How does Dr. Martens compare to Wickes Group?

Does the media refer more to DOCS or WIX?

Which has better valuation & earnings, DOCS or WIX?

Which has more risk and volatility, DOCS or WIX?

Is DOCS or WIX more profitable?

Do analysts rate DOCS or WIX?

Is DOCS or WIX a better dividend stock?

Do insiders & institutionals believe in DOCS or WIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools